Evidence map›Paper›PMID 30500825›Full record

ArticlePLoS genetics2018

De novo mutations in the GTP/GDP-binding region of RALA, a RAS-like small GTPase, cause intellectual disability and developmental delay.

Susan M Hiatt, Matthew B Neu, Ryne C Ramaker, Andrew A Hardigan, Jeremy W Prokop, Miroslava Hancarova, Darina Prchalova, Marketa Havlovicova, Jan Prchal, Viktor Stranecky and 23 more

Abstract read
In one paragraph

Article in PLoS genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Regulation of Ras Signaling by S-Nitrosylation.Antioxidants (Basel, Switzerland) · 2023
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Brain Somatic Variant in Ras-Like Small GTPaseFrontiers in behavioral neuroscience · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Susan M HiattHudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America.
Matthew B NeuHudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America.ORCID 0000-0003-0808-6921
Ryne C RamakerHudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America.
Andrew A HardiganHudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America.
Jeremy W ProkopDepartment of Pediatrics and Human Development, Michigan State University, East Lansing, MI, United States of America.ORCID 0000-0002-1818-9695
Miroslava HancarovaDepartment of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.ORCID 0000-0001-6772-8862
Darina PrchalovaDepartment of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Marketa HavlovicovaDepartment of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Jan PrchalLaboratory of NMR Spectroscopy, University of Chemistry and Technology, Prague, Czech Republic.
Viktor StraneckyDepartment of Pediatrics and Adolescent Medicine, Diagnostic and Research Unit for Rare Diseases, Charles University 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.ORCID 0000-0002-2599-6479
Dwight K C YimKaiser Permanente-Hawaii, Honolulu, HI, United States of America.
Zöe PowisDepartment of Emerging Genetic Medicine, Ambry Genetics, Aliso Viejo, CA, United States of America.ORCID 0000-0002-1347-4358
Boris KerenDepartment of Genetics, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0001-6172-8247
Caroline NavaDepartment of Genetics, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0003-1272-0518
Cyril MignotDepartment of Genetics, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0002-3462-3463
Marlene RioCentre de Référence Déficiences Intellectuelles de Causes Rares, Paris, France.ORCID 0000-0003-2049-5058
Anya Revah-PolitiInstitute for Genomic Medicine, Columbia University Medical Center, New York, NY, United States of America.
Parisa HematiInstitute for Genomic Medicine, Columbia University Medical Center, New York, NY, United States of America.ORCID 0000-0001-6347-552X
Nicholas StongInstitute for Genomic Medicine, Columbia University Medical Center, New York, NY, United States of America.ORCID 0000-0002-0678-637X
Alejandro D IglesiasDivision of Clinical Genetics, Department of Pediatrics, Columbia University Medical Center, New York, NY, United States of America.
Sharon F SuchyGeneDx, Gaithersburg, MD, United States of America.
Rebecca WillaertGeneDx, Gaithersburg, MD, United States of America.
Ingrid M WentzensenGeneDx, Gaithersburg, MD, United States of America.
Patricia G WheelerArnold Palmer Hospital, Division of Genetics, Orlando, FL, United States of America.
Lauren BrickDepartment of Genetics, McMaster Children's Hospital, Hamilton, Ontario, Canada.ORCID 0000-0001-5586-0284
Mariya KozenkoDepartment of Genetics, McMaster Children's Hospital, Hamilton, Ontario, Canada.
Anna C E HurstDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL, United States of America.ORCID 0000-0002-9765-9703
James W WhelessDivision of Pediatric Neurology, University of Tennessee Health Science Center, Neuroscience Institute & Le Bonheur Comprehensive Epilepsy Program, Memphis, TN, United States of America.
Yves LacassieDivision of Clinical Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, United States of America.
Richard M MyersHudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America.
Gregory S BarshHudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America.ORCID 0000-0002-0838-1042
Zdenek SedlacekDepartment of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Gregory M CooperHudsonAlpha Institute for Biotechnology, Huntsville, AL, United States of America.ORCID 0000-0001-5509-9923

Funding

South-seq: DNA sequencing for newborn nurseries in the SouthU01HG007301 · NHGRI · HUDSON-ALPHA INSTITUTE FOR BIOTECHNOLOGY · PI BARSH, GREGORY STEFAN, COOPER, GREGORY MICHAEL · 2017 to 2021
$11.9M
Genomic Diagnosis in Children with Developmental DelayUM1HG007301 · NHGRI · HUDSON-ALPHA INSTITUTE FOR BIOTECHNOLOGY · PI COOPER, GREGORY MICHAEL, MYERS, RICHARD M · 2013 to 2016
$7.5M
Using a Sequence-to-Structure-to-Function Approach to Functionally Characterize Protein Coding Missense Mutations in the Human and Rat GenomesK01ES025435 · NIEHS · MICHIGAN STATE UNIVERSITY · PI PROKOP, JEREMY WILLIAM · 2014 to 2018
$489k
NHGRI NIH HHS U01 HG007301NHGRI NIH HHS UM1 HG007301NIEHS NIH HHS K01 ES025435
6 · The paper itself

Abstract

Mutations that alter signaling of RAS/MAPK-family proteins give rise to a group of Mendelian diseases known as RASopathies. However, among RASopathies, the matrix of genotype-phenotype relationships is still incomplete, in part because there are many RAS-related proteins and in part because the phenotypic consequences may be variable and/or pleiotropic. Here, we describe a cohort of ten cases, drawn from six clinical sites and over 16,000 sequenced probands, with de novo protein-altering variation in RALA, a RAS-like small GTPase. All probands present with speech and motor delays, and most have intellectual disability, low weight, short stature, and facial dysmorphism. The observed rate of de novo RALA variants in affected probands is significantly higher (p = 4.93 x 10(-11)) than expected from the estimated random mutation rate. Further, all de novo variants described here affect residues within the GTP/GDP-binding region of RALA; in fact, six alleles arose at only two codons, Val25 and Lys128. The affected residues are highly conserved across both RAL- and RAS-family genes, are devoid of variation in large human population datasets, and several are homologous to positions at which disease-associated variants have been observed in other GTPase genes. We directly assayed GTP hydrolysis and RALA effector-protein binding of the observed variants, and found that all but one tested variant significantly reduced both activities compared to wild-type. The one exception, S157A, reduced GTP hydrolysis but significantly increased RALA-effector binding, an observation similar to that seen for oncogenic RAS variants. These results show the power of data sharing for the interpretation and analysis of rare variation, expand the spectrum of molecular causes of developmental disability to include RALA, and provide additional insight into the pathogenesis of human disease caused by mutations in small GTPases.

Indexed as

MutationDevelopmental DisabilitiesFaciesGenotypeGuanosine DiphosphateGuanosine TriphosphateHumansIntellectual DisabilityMitochondrial ProteinsModels, MolecularMutation, MissensePhenotypeProtein ConformationProtein Interaction Domains and Motifsral GTP-Binding Proteinsras ProteinsGuanosine DiphosphateGuanosine TriphosphateMitochondrial ProteinsRAB40AL protein, humanRALA protein, humanral GTP-Binding Proteinsras Proteins

Identifiers

PMID30500825
PMCPMC6291162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.